Loading...

BIO-key International

Nasdaq:BKYI
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BKYI
Nasdaq
$16M
Market Cap
  1. Home
  2. US
  3. Software
Company description

BIO-key International, Inc. develops and markets fingerprint biometric identification and identity verification technologies, authentication-transaction security technologies, and related identity management and credentialing biometric hardware and software solutions. The last earnings update was 126 days ago. More info.


Add to Portfolio Compare Print
  • BIO-key International has significant price volatility in the past 3 months.
BKYI Share Price and Events
7 Day Returns
8.3%
NasdaqCM:BKYI
2.4%
US Software
1.2%
US Market
1 Year Returns
-40.9%
NasdaqCM:BKYI
25.6%
US Software
3%
US Market
BKYI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BIO-key International (BKYI) 8.3% -15.2% -8.6% -40.9% -40.9% -79.7%
US Software 2.4% 5.5% 19.8% 25.6% 110.4% 139.4%
US Market 1.2% 2.1% 14.6% 3% 39% 43.5%
1 Year Return vs Industry and Market
  • BKYI underperformed the Software industry which returned 25.6% over the past year.
  • BKYI underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
BKYI
Industry
5yr Volatility vs Market
Related Companies

Value

 Is BIO-key International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BIO-key International. This is due to cash flow or dividend data being unavailable. The share price is $1.17.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BIO-key International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BIO-key International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:BKYI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.68
NasdaqCM:BKYI Share Price ** NasdaqCM (2019-03-20) in USD $1.17
United States of America Software Industry PE Ratio Median Figure of 84 Publicly-Listed Software Companies 53.03x
United States of America Market PE Ratio Median Figure of 3,058 Publicly-Listed Companies 17.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BIO-key International.

NasdaqCM:BKYI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BKYI Share Price ÷ EPS (both in USD)

= 1.17 ÷ -0.68

-1.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BIO-key International is loss making, we can't compare its value to the US Software industry average.
  • BIO-key International is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does BIO-key International's expected growth come at a high price?
Raw Data
NasdaqCM:BKYI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
121.5%per year
United States of America Software Industry PEG Ratio Median Figure of 66 Publicly-Listed Software Companies 3.6x
United States of America Market PEG Ratio Median Figure of 2,103 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BIO-key International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BIO-key International's assets?
Raw Data
NasdaqCM:BKYI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $0.84
NasdaqCM:BKYI Share Price * NasdaqCM (2019-03-20) in USD $1.17
United States of America Software Industry PB Ratio Median Figure of 220 Publicly-Listed Software Companies 5.84x
United States of America Market PB Ratio Median Figure of 5,156 Publicly-Listed Companies 1.89x
NasdaqCM:BKYI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BKYI Share Price ÷ Book Value per Share (both in USD)

= 1.17 ÷ 0.84

1.39x

* Primary Listing of BIO-key International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BIO-key International is good value based on assets compared to the US Software industry average.
X
Value checks
We assess BIO-key International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Software industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Software industry average (and greater than 0)? (1 check)
  5. BIO-key International has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BIO-key International expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
121.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BIO-key International expected to grow at an attractive rate?
  • BIO-key International's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • BIO-key International's earnings growth is expected to exceed the United States of America market average.
  • BIO-key International's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:BKYI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:BKYI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 121.5%
NasdaqCM:BKYI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 58.6%
United States of America Software Industry Earnings Growth Rate Market Cap Weighted Average 16.1%
United States of America Software Industry Revenue Growth Rate Market Cap Weighted Average 10.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:BKYI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:BKYI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 23 5 1
2019-12-31 15 0 1
2018-12-31 8 -5 1
NasdaqCM:BKYI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 5 -2 -7
2018-06-30 6 -2 -6
2018-03-31 6 -2 -6
2017-12-31 6 -2 -5
2017-09-30 5 -3 -6
2017-06-30 4 -3 -6
2017-03-31 4 -4 -5
2016-12-31 3 -4 -5
2016-09-30 3 -18 -5
2016-06-30 3 -17 -5
2016-03-31 5 -16 -2
2015-12-31 5 -16 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BIO-key International's earnings are expected to grow significantly at over 20% yearly.
  • BIO-key International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:BKYI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from BIO-key International Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BKYI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 0.18 0.18 0.18 1.00
2019-12-31 0.00 0.00 0.00 1.00
2018-12-31 -0.39 -0.39 -0.39 1.00
NasdaqCM:BKYI Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.68
2018-06-30 -0.66
2018-03-31 -0.82
2017-12-31 -0.76
2017-09-30 -0.98
2017-06-30 -0.94
2017-03-31 -0.90
2016-12-31 -0.89
2016-09-30 -0.91
2016-06-30 -0.86
2016-03-31 -0.44
2015-12-31 -0.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BIO-key International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BIO-key International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BIO-key International has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BIO-key International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BIO-key International's growth in the last year to its industry (Software).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BIO-key International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BIO-key International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BIO-key International's 1-year growth to the US Software industry average as it is not currently profitable.
Earnings and Revenue History
BIO-key International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BIO-key International Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BKYI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 5.38 -6.81 4.97 1.41
2018-06-30 5.59 -5.54 5.16 1.41
2018-03-31 5.73 -5.84 5.52 1.56
2017-12-31 6.30 -5.04 5.68 1.66
2017-09-30 4.95 -6.07 5.77 1.75
2017-06-30 4.43 -5.60 5.46 1.90
2017-03-31 3.96 -5.19 5.07 2.01
2016-12-31 2.98 -4.99 4.44 2.01
2016-09-30 2.95 -5.02 4.04 1.97
2016-06-30 3.19 -4.76 4.13 1.81
2016-03-31 5.04 -2.43 4.07 1.64
2015-12-31 5.26 -1.99 4.12 1.56
2015-09-30 4.54 -1.76 3.96 1.51
2015-06-30 5.16 -0.73 3.94 1.47
2015-03-31 3.29 -2.51 3.85 1.55
2014-12-31 4.01 -1.88 3.67 1.63
2014-09-30 3.38 -2.31 3.46 1.72
2014-06-30 2.53 -3.04 3.22 1.75
2014-03-31 2.55 -2.57 2.90 1.57
2013-12-31 1.99 -2.58 2.78 1.34
2013-09-30 3.14 -1.17 2.67 1.13
2013-06-30 3.12 -0.62 2.26 0.98
2013-03-31 3.23 -0.68 2.42 0.96
2012-12-31 3.84 0.00 2.29 0.95
2012-09-30 2.90 -1.49 2.74 0.98
2012-06-30 3.06 -1.79 3.03 1.05
2012-03-31 3.51 -1.77 2.93 1.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BIO-key International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BIO-key International has efficiently used its assets last year compared to the US Software industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BIO-key International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BIO-key International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Software industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BIO-key International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BIO-key International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BIO-key International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BIO-key International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BIO-key International has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BIO-key International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BIO-key International has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BIO-key International Company Filings, last reported 5 months ago.

NasdaqCM:BKYI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 11.79 0.00 1.05
2018-06-30 11.46 0.00 0.30
2018-03-31 12.61 0.00 1.30
2017-12-31 13.75 0.00 0.29
2017-09-30 13.31 0.00 0.97
2017-06-30 13.41 0.00 0.99
2017-03-31 14.00 0.00 1.16
2016-12-31 15.45 0.00 1.06
2016-09-30 14.22 0.00 0.18
2016-06-30 15.40 0.00 2.01
2016-03-31 16.93 0.00 3.47
2015-12-31 18.15 0.00 4.32
2015-09-30 -0.28 0.71 0.07
2015-06-30 0.76 0.00 0.28
2015-03-31 -0.02 0.12 0.30
2014-12-31 0.76 0.00 0.84
2014-09-30 -0.26 0.00 0.17
2014-06-30 -0.24 0.00 0.52
2014-03-31 0.73 0.00 0.59
2013-12-31 1.05 0.00 2.02
2013-09-30 -0.95 0.50 0.23
2013-06-30 -1.19 0.50 0.10
2013-03-31 -0.66 0.50 0.45
2012-12-31 -1.22 0.32 0.08
2012-09-30 -1.71 0.35 0.11
2012-06-30 -1.48 0.35 0.05
2012-03-31 -0.89 0.35 0.21
  • BIO-key International has no debt.
  • BIO-key International currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BIO-key International has less than a year of cash runway based on current free cash flow.
  • BIO-key International has less than a year of cash runway if free cash flow continues to reduce at historical rates of -63% each year.
X
Financial health checks
We assess BIO-key International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BIO-key International has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BIO-key International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BIO-key International dividends.
If you bought $2,000 of BIO-key International shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BIO-key International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BIO-key International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:BKYI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Software Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2004 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:BKYI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BIO-key International has not reported any payouts.
  • Unable to verify if BIO-key International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BIO-key International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BIO-key International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BIO-key International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BIO-key International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BIO-key International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BIO-key International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike DePasquale
COMPENSATION $842,544
AGE 63
TENURE AS CEO 16.2 years
CEO Bio

Mr. Michael W. DePasquale, also known as Mike, has been the Chief Executive Officer of BIO-key International Inc. since August 2006. Mr. DePasquale served as the Chief Executive Officer of BIO-key International from January 3, 2003 to July 2005 and Co-Chief Executive Officer from July 2005 to August 2006. He has more than 30 years of executive management, sales and marketing experience. Prior to BIO-key International Inc., he served as the President and Chief Executive Officer at Prism eSolutions, Inc since February 2001. From December 1999 to December 2000, Mr. DePasquale served as Group Vice President for WRC Media, a New York based distributor of supplemental education products and software. He served as Senior Vice President of Jostens Learning Corp., a California based provider of multi media curriculum, from January 1996 to December 1999. Prior to Jostes, he held sales and marketing management positions with McGraw-Hill and Digital Equipment Corporation. He has been the Chairman of BIO-key International Inc. since January 29, 2014. He has been a Director at BIO-key International Inc. since January 3, 2007. Mr. DePasquale earned a Bachelor of Science degree from the New Jersey Institute of Technology.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BIO-key International management team in years:

7.5
Average Tenure
58
Average Age
  • The average tenure for the BIO-key International management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike DePasquale

TITLE
Chairman & CEO
COMPENSATION
$843K
AGE
63
TENURE
16.2 yrs

Ceci Welch

TITLE
Chief Financial Officer
COMPENSATION
$463K
AGE
58
TENURE
9.3 yrs

Mira LaCous

TITLE
Chief Technology Officer
COMPENSATION
$212K
AGE
56
TENURE
5 yrs

Scott Mahnken

TITLE
Vice President of Marketing
COMPENSATION
$156K
AGE
58
TENURE
8.1 yrs

Jim Sullivan

TITLE
Senior Vice President of Strategy & Business Development
AGE
51
TENURE
6.9 yrs

Fred Corsentino

TITLE
Chief Revenue Officer
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the BIO-key International board of directors in years:

3.3
Average Tenure
58
Average Age
  • The tenure for the BIO-key International board of directors is about average.
Board of Directors

Mike DePasquale

TITLE
Chairman & CEO
COMPENSATION
$843K
AGE
63
TENURE
5.2 yrs

Thomas Bush

TITLE
Independent Director
COMPENSATION
$29K
AGE
65
TENURE
5.2 yrs

Tom Gilley

TITLE
Independent Director
COMPENSATION
$29K
AGE
57
TENURE
5.2 yrs

Bob Michel

TITLE
Independent Director
COMPENSATION
$26K
AGE
61
TENURE
1.9 yrs

Kelvin Wong

TITLE
Director
COMPENSATION
$344K
AGE
55
TENURE
3.3 yrs

Jianhui Yao

TITLE
Director
COMPENSATION
$3K
AGE
46
TENURE
3.3 yrs

Pieter Knook

TITLE
Independent Director
COMPENSATION
$28K
AGE
59
TENURE
2.8 yrs

Fabian Shin

TITLE
Independent Director
AGE
49
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
28. Nov 18 Buy Robert Michel Individual 28. Nov 18 28. Nov 18 5,000 $1.27 $6,350
04. Jun 18 Buy Kwok Wong Individual 31. May 18 31. May 18 7,073 $3.60 $25,463
05. Apr 18 Buy Kwok Wong Individual 03. Apr 18 03. Apr 18 91,820 $3.60 $330,552
X
Management checks
We assess BIO-key International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BIO-key International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does BIO-key International, Inc.'s (NASDAQ:BKYI) CEO Pay Matter?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Mike DePasquale's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m

Simply Wall St -

How Much Of BIO-key International, Inc. (NASDAQ:BKYI) Do Insiders Own?

Every investor in BIO-key International, Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … BIO-key International is not a large company by global standards.

Simply Wall St -

BIO-key International, Inc. (NASDAQ:BKYI): What Does Its Beta Value Mean For Your Portfolio?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

What does BIO-key International, Inc.'s (NASDAQ:BKYI) Balance Sheet Tell Us About Its Future?

(NASDAQ:BKYI), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Does BKYI's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Read This Before Selling BIO-key International, Inc. (NASDAQ:BKYI) Shares

So we'll take a look at whether insiders have been buying or selling shares in BIO-key International, Inc. … BIO-key International Insider Transactions Over The Last Year. … In total, BIO-key International insiders bought more than they sold over the last year

Simply Wall St -

Is BIO-key International Inc's (NASDAQ:BKYI) CEO Pay Fair?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Mike DePasquale's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that BIO-key International Inc has a market cap of US$17m, and is paying total annual CEO compensation of US$843k

Simply Wall St -

BIO-key International Inc (NASDAQ:BKYI) Is Expected To Breakeven

BIO-key International Inc's (NASDAQ:BKYI):. … BIO-key International, Inc. … The US$17m market-cap posted a loss in its most recent financial year of -US$5m and a latest trailing-twelve-month loss of -US$6m leading to an even wider gap between loss and breakeven.

Simply Wall St -

Who Are The Major Shareholders In BIO-key International Inc (NASDAQ:BKYI)?

In this article, I will take a quick look at BIO-key International Inc’s (NASDAQ:BKYI) recent ownership structure – an unconventional investing subject, but an important one. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

Should You Worry About BIO-key International Inc's (NASDAQ:BKYI) Cash Runway?

Trailing twelve-month data shows us that BIO-key International Inc's (NASDAQ:BKYI) earnings loss has accumulated to -US$5.84m. … Although some investors expected this, their belief in the path to profitability for BIO-key International may be wavering. … Additional cash raising may dilute the value of your shares, and since BIO-key International is currently burning more cash than it is making, it’s likely the business will need funding for future growth.

Simply Wall St -

When Can We Expect A Profit From BIO-key International Inc (NASDAQ:BKYI)?

The US$27.07m market-cap posted a loss in its most recent financial year of -US$5.04m and a latest trailing-twelve-month loss of -US$5.84m leading to an even wider gap between loss and breakeven? … I’ve put together a brief outline of industry analyst expectations for BKYI, its year of breakeven and its implied growth rate … Expectation from Software analysts is BKYI is on the verge of breakeven.

Simply Wall St -

Company Info

Description

BIO-key International, Inc. develops and markets fingerprint biometric identification and identity verification technologies, authentication-transaction security technologies, and related identity management and credentialing biometric hardware and software solutions. Its solutions enable application developers, value added resellers, and channel partners to integrate fingerprint biometrics into their applications. The company’s products include Vector Segment Technology SDK, a biometric software development kit that provides developers the ability to incorporate its biometric capabilities into their respective product offerings or infrastructure; Intelligent Image Indexing, a biometric identification solution that offers one-to-many and one-to-one user identification; and Biometric Service Provider, which provides support for the BioAPI for a compliant interface to applications using biometrics for verification and identification. Its products also comprise ID Director, a solution for single sign on integration with CA Technologies SiteMinder, Oracle’s Fusion Middleware SSO, IBM Tivoli Access Manager, and other solutions; and WEB-key, an authentication-transaction security technology to conduct identification and identity verification transactions in insecure environments, such as the world wide Web or off-site cloud environments. The company also sells third-party hardware components. BIO-key International, Inc. markets its products through its direct sales force, as well as through distributors, resellers, integrators, and partner networks to government and corporate customers primarily in North America. It has strategic partnership with Quantum Business Advisory to bring its software and hardware solutions to enterprises in India. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.

Details
Name: BIO-key International, Inc.
BKYI
Exchange: NasdaqCM
Founded: 1993
$16,354,105
13,977,868
Website: http://www.bio-key.com
Address: BIO-key International, Inc.
Building A,
Suite E,
Wall,
New Jersey, 07719,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BKYI Common Stock Nasdaq Capital Market US USD 24. Feb 1997
Number of employees
Current staff
Staff numbers
25
BIO-key International employees.
Industry
Systems Software
Software
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/20 23:33
End of day share price update: 2019/03/20 00:00
Last estimates confirmation: 2018/11/15
Last earnings filing: 2018/11/14
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.